Thuja Capital

Alesta Therapeutics is engaged in developing innovative therapies aimed at treating cancer by targeting chronic stress response pathways. The company focuses on small molecule biotech programs that address synthetic lethal metabolic dependencies essential for cancer cell survival. By targeting specific control mechanisms involved in these pathways, Alesta Therapeutics aims to provide new therapeutic approaches that can effectively disrupt the growth of cancer cells, thereby enhancing treatment options for patients.

Alveron Pharma is focused on developing innovative treatments for hemorrhagic stroke and various thromboembolic disorders, addressing significant unmet medical needs. The company’s lead product, OKL-1111, is an injection solution designed to reduce hematoma expansion in cases of intracranial hemorrhage, moving away from complex pre-treatment processes. Additionally, Alveron is working on a cyclodextrin-based anticoagulant reversal drug, which aims to provide effective solutions for excessive bleeding related to conditions such as hemophilia, trauma, and surgical procedures. By advancing its coagulation technology, Alveron Pharma strives to enhance therapeutic options for medical practitioners dealing with acute and long-term bleeding complications.

Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of Tumor-Associated Carbohydrate Antigens (TACAs) as innovative targets for cancer therapy. Originating as a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Tacalyx leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures are essential for generating and identifying antibodies aimed at developing new therapeutics. TACAs are characterized by their specific expression in tumors, which arises from abnormal glycosylation and is associated with promoting metastasis, angiogenesis, and immune system suppression. By combining sophisticated synthesis capabilities with comprehensive analysis and screening, Tacalyx aims to create novel immunotherapies that effectively stimulate anti-cancer responses.

Artica Therapeutics focuses on biotechnological research and development aimed at creating innovative therapies for severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods to facilitate the rapid advancement of drug candidates. This approach enhances the efficiency of the drug discovery process, ultimately enabling healthcare professionals to provide effective treatments for patients suffering from these challenging conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, expanding its impact within the healthcare sector.

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.

FundaMental Pharma is a neuroscience company focused on developing innovative treatments for neurological diseases at the preclinical stage. The company creates neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. Utilizing peptides and gene therapy, FundaMental Pharma specializes in diagnosing polymorphisms and is dedicated to developing a novel class of drugs that target untreatable neurological conditions. Through its research, the company seeks to provide pharmacological solutions for patients suffering from various challenging neurological disorders.

AstriVax is focused on developing novel vaccines that address significant challenges in the field of vaccinology. The company aims to create vaccines that minimize cold chain requirements while providing broad and long-lasting protection against a range of viruses and other pathogens. By pursuing initial clinical validation of its platform technology, AstriVax seeks to establish a comprehensive vaccination pipeline to enhance treatment options in the healthcare sector.

InnoSIGN specializes in mRNA-based pathway activity profiling technology, aimed at advancing precision medicine by offering deeper insights into disease mechanisms. The company leverages a comprehensive library of pathway activity profiles to enhance diagnostics and facilitate drug discovery. It provides researchers with quantitative PCR (qPCR) tests designed for decentralized use, which are available through a service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN seeks to transform the understanding and treatment of various diseases.

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.

Alveron Pharma is focused on developing innovative treatments for hemorrhagic stroke and various thromboembolic disorders, addressing significant unmet medical needs. The company’s lead product, OKL-1111, is an injection solution designed to reduce hematoma expansion in cases of intracranial hemorrhage, moving away from complex pre-treatment processes. Additionally, Alveron is working on a cyclodextrin-based anticoagulant reversal drug, which aims to provide effective solutions for excessive bleeding related to conditions such as hemophilia, trauma, and surgical procedures. By advancing its coagulation technology, Alveron Pharma strives to enhance therapeutic options for medical practitioners dealing with acute and long-term bleeding complications.

EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.

Kinetyx Sciences Inc., established in 2020 and headquartered in Calgary, Canada, specializes in developing in-shoe sensor-based solutions for various sports and performance applications. Their core product is sensory insoles that gather high-fidelity data at the point where the foot meets the ground, providing laboratory-quality data in real-world settings. This data enables users to gain insights into their movements, helping to enhance athletic performance, prevent injuries, and facilitate recovery.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

NutriLeads is a startup focused on developing innovative nutritional ingredients with clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to support physiological processes and modulate the gut microbiome. NutriLeads collaborates with industry partners to identify promising lead ingredients, create sustainable and commercially viable production processes, and initiate scientific and clinical programs that validate the health effects of its offerings. By doing so, NutriLeads aims to enhance nutritional health innovation in the food industry, ultimately providing consumers and patients with access to dietary supplements and specialized functional food and beverage products that deliver these benefits.

Indigo Diabetes, established in 2016 and headquartered in Ghent, Belgium, specializes in developing innovative, non-invasive glucose monitoring solutions. The company's flagship product is an invisible, photonics-based sensor that is inserted under the skin, continuously measuring blood sugar levels, thereby eliminating the need for traditional finger pricks. Indigo Diabetes aims to enhance the lives of people with diabetes by providing accurate glucose monitoring with an improved user experience.

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Mellon Medical B.V., established in 2013 and headquartered in Nijmegen, the Netherlands, specializes in the development and marketing of innovative suturing tools designed for surgical applications. The company focuses on creating instruments that enable surgeons to perform single-handed stitching, thereby enhancing the efficiency and effectiveness of suturing tubular and layered structures during medical procedures. By providing advanced suturing solutions, Mellon Medical aims to improve patient outcomes and support medical specialists in delivering high-quality healthcare.

ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.

NutriLeads is a startup focused on developing innovative nutritional ingredients with clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to support physiological processes and modulate the gut microbiome. NutriLeads collaborates with industry partners to identify promising lead ingredients, create sustainable and commercially viable production processes, and initiate scientific and clinical programs that validate the health effects of its offerings. By doing so, NutriLeads aims to enhance nutritional health innovation in the food industry, ultimately providing consumers and patients with access to dietary supplements and specialized functional food and beverage products that deliver these benefits.

Indigo Diabetes, established in 2016 and headquartered in Ghent, Belgium, specializes in developing innovative, non-invasive glucose monitoring solutions. The company's flagship product is an invisible, photonics-based sensor that is inserted under the skin, continuously measuring blood sugar levels, thereby eliminating the need for traditional finger pricks. Indigo Diabetes aims to enhance the lives of people with diabetes by providing accurate glucose monitoring with an improved user experience.

MILabs specializes in high-end molecular imaging solutions designed for biomedical, pharmaceutical, and university research. The company manufactures multimodal and integrated imaging systems, including micro-PET, micro-SPECT, micro-CT scanners, and optical tomography systems. These advanced technologies are utilized in the diagnosis of various diseases, such as diabetes, cancer, and neurodegenerative disorders. MILabs aims to provide clients with diagnostic tools that are characterized by user-friendly operation, facilitating efficient workflows in research and clinical settings. Their systems play a significant role in the global development of new diagnostic methods.

NightBalance B.V., established in 2009, is a medical technology company spun out from TU Delft. It specializes in developing innovative solutions to improve patients' sleep, with a focus on treating positional obstructive sleep apnea. The company's flagship product, a Sleep Position Trainer, uses smart technology to monitor and enhance sleep behavior, enabling users to achieve more comfortable and restful nights.

NutriLeads is a startup focused on developing innovative nutritional ingredients with clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to support physiological processes and modulate the gut microbiome. NutriLeads collaborates with industry partners to identify promising lead ingredients, create sustainable and commercially viable production processes, and initiate scientific and clinical programs that validate the health effects of its offerings. By doing so, NutriLeads aims to enhance nutritional health innovation in the food industry, ultimately providing consumers and patients with access to dietary supplements and specialized functional food and beverage products that deliver these benefits.

FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.

Hemics is a medical device company focused on enhancing the quality of life for patients with Rheumatoid Arthritis (RA) through innovative imaging technology. The company develops non-invasive devices that utilize a patented Optical Inflammation Detection technology, which allows for the fast and objective quantification of inflammation. This technology aids rheumatologists in monitoring and assessing disease activity in the joints, particularly in the hands, facilitating more effective treatment strategies. Founded as a spin-out from Royal Philips Electronics, Hemics aims to provide an operator-independent solution that supports rheumatologists in their clinical assessments of inflammatory conditions associated with RA.

Cristal Therapeutics BV is a clinical-stage pharmaceutical company based in Maastricht, the Netherlands, founded in 2011. The company specializes in developing nanomedicines using its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted therapy. This advanced technology aims to enhance the efficacy of both new and existing drugs by improving their delivery to specific tissues and cells, thereby addressing significant medical needs, particularly in cancer treatment. Cristal Therapeutics focuses on creating versatile nanomedicine solutions that can facilitate better outcomes in various therapeutic areas through innovative polymeric constructs.

EnCare Biotech B.V. is a biopharmaceutical company based in Utrecht, the Netherlands, established in 2014. The company specializes in the development of therapeutic monoclonal antibodies, particularly focusing on its Fibronectin-EDA monoclonal antibody aimed at preventing chronic heart failure following acute myocardial infarction. EnCare's approach integrates a solid scientific foundation with expertise in manufacturing, regulatory affairs, and clinical development, supported by a network of specialists in these fields. The management team has extensive experience in business development and has successfully executed partnerships across the industry. EnCare operates with a lean business model, maintaining in-house control over key functions while outsourcing operational activities to top-tier external providers. This structure allows EnCare to focus on delivering innovative therapies that enhance patient outcomes in heart failure prevention.

NightBalance B.V., established in 2009, is a medical technology company spun out from TU Delft. It specializes in developing innovative solutions to improve patients' sleep, with a focus on treating positional obstructive sleep apnea. The company's flagship product, a Sleep Position Trainer, uses smart technology to monitor and enhance sleep behavior, enabling users to achieve more comfortable and restful nights.

Mellon Medical B.V., established in 2013 and headquartered in Nijmegen, the Netherlands, specializes in the development and marketing of innovative suturing tools designed for surgical applications. The company focuses on creating instruments that enable surgeons to perform single-handed stitching, thereby enhancing the efficiency and effectiveness of suturing tubular and layered structures during medical procedures. By providing advanced suturing solutions, Mellon Medical aims to improve patient outcomes and support medical specialists in delivering high-quality healthcare.

Hemics is a medical device company focused on enhancing the quality of life for patients with Rheumatoid Arthritis (RA) through innovative imaging technology. The company develops non-invasive devices that utilize a patented Optical Inflammation Detection technology, which allows for the fast and objective quantification of inflammation. This technology aids rheumatologists in monitoring and assessing disease activity in the joints, particularly in the hands, facilitating more effective treatment strategies. Founded as a spin-out from Royal Philips Electronics, Hemics aims to provide an operator-independent solution that supports rheumatologists in their clinical assessments of inflammatory conditions associated with RA.

TheraSolve NV is a medical technology company focused on enhancing medication adherence through innovative and user-friendly solutions. The company's flagship product, the Memopatch, is a skin patch designed to support and remind patients when to take their medications, thereby improving compliance with treatment regimens. By leveraging its patented technology platform, TheraSolve aims to motivate a wide range of patients to follow prescribed medication schedules and engage in other health-promoting activities. The company is committed to providing cost-effective tools that address the challenges of medication adherence, ultimately contributing to better health outcomes.

NightBalance B.V., established in 2009, is a medical technology company spun out from TU Delft. It specializes in developing innovative solutions to improve patients' sleep, with a focus on treating positional obstructive sleep apnea. The company's flagship product, a Sleep Position Trainer, uses smart technology to monitor and enhance sleep behavior, enabling users to achieve more comfortable and restful nights.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.

Cavadis is a Dutch biomedical company focused on cardiovascular risk assessment. It specializes in developing prognostic tests aimed at identifying patients at risk for cardiovascular diseases, including heart attacks and strokes. By discovering novel biomarkers that are more predictive of cardiovascular events than traditional risk factors, Cavadis enables healthcare professionals to personalize treatment plans. The company aims to create clinically meaningful risk stratification tools that enhance patient outcomes through tailored interventions.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.

Bioceros B.V. is a biopharmaceutical research and development contract organization based in Utrecht, the Netherlands, founded in 2003. The company specializes in the early pre-clinical development of recombinant proteins, particularly monoclonal antibodies. Bioceros provides a comprehensive range of technical and scientific services, including assay development, molecular biology, cell biology, immunology, protein expression, upscaling, fermentation, protein purification, and consulting. These services are aimed at biotech companies, academic institutions, and pharmaceutical firms, enabling them to access fully integrated programs from DNA to drug product. This approach supports the advancement of medicinal products and ultimately aids in addressing patient needs.

Cavadis is a Dutch biomedical company focused on cardiovascular risk assessment. It specializes in developing prognostic tests aimed at identifying patients at risk for cardiovascular diseases, including heart attacks and strokes. By discovering novel biomarkers that are more predictive of cardiovascular events than traditional risk factors, Cavadis enables healthcare professionals to personalize treatment plans. The company aims to create clinically meaningful risk stratification tools that enhance patient outcomes through tailored interventions.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. It specializes in developing innovative therapeutics for acute and critical care, focusing on areas such as hematology, antithrombosis, and oncology. The company's research efforts aim to create advanced biopharmaceutics that address urgent medical needs, providing new treatment options for patients with critical diseases.

Breonics focuses on biomedical research and development, specifically in the area of organ and tissue transplants. The company has developed Exsanguinous Metabolic Support (EMS) technology, which significantly expands the criteria for organ donation. This innovative technology addresses the limitations that currently restrict access to potential kidney donors, allowing healthcare practitioners to maintain the oxidative metabolism and function of organs while they are isolated from the human body. As a result, EMS has the potential to double the number of transplantable kidneys available worldwide, ultimately improving outcomes for patients in need of transplants.

Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets biological products for the biosurgical and immunotherapy markets.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Vernalis Limited is a commercial stage pharmaceutical company based in Cambridge, United Kingdom, focused on the research, development, and commercialization of pharmaceutical products for various medical disorders. The company offers several products, including Tuzistra XR for the U.S. prescription cough-cold market, Moxatag, a once-daily amoxicillin formulation for treating tonsillitis and pharyngitis, and frovatriptan for acute migraine treatment. Vernalis engages in developing and commercializing additional products through licensing agreements, emphasizing its strategy of combining internal research with collaborations with global pharmaceutical companies. Its research laboratories employ advanced techniques such as fragment-based approaches, structural biology, and medicinal chemistry to facilitate drug discovery. Established in 1988, Vernalis operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.